Aurobindo Pharma gets USFDA nod for Tofacitinib tablets

5 Jun 2026via SiliconindiaSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Aurobindo Pharma gets USFDA nod for Tofacitinib tablets – a generic version of Xeljanz used to treat rheumatoid arthritis. The approval allows the company to launch the 5 mg tablet in the US market, expanding its portfolio. This adds to Aurobindo’s growing list of ~400 ANDA approvals.
📊 STOCKS: AUROPHARMA | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA

#USFDA#approval#generic#Aurobindo

Stocks mentioned

AUROPHARMAAUROPHARMA

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →